gc-1 peptide Peptide - GC 1 peptidebodybuilding Gc Unveiling the Potential of GC-1 Peptide: A Deep Dive into its Thyromimetic Properties

GC-1 peptidebenefits The GC-1 peptide, also widely recognized as Sobetirome, is a synthetic compound that has garnered significant scientific interest due to its potent thyromimetic properties.作者：E Rinaldini·2021·被引用次数：2—This study aims to demonstrate TH-selective signaling effects on reproductive and lactational performance in hypothyroid rats. As a thyromimetic drug that binds to the thyroid hormone receptor TRβ1 preferentially, GC-1 acts by mimicking the actions of natural thyroid hormones, but with a crucial distinction: its selective interaction with specific thyroid hormone receptors. This selectivity is key to understanding its potential therapeutic applications and is a central theme in ongoing research.

At its core, the GC-1 peptide functions as a selective agonist for the thyroid hormone receptor beta (TRβ)作者：X Chu·2025—A new efficient synthesis of TRβ-selective thyromimeticGC-1is described. The present strategy employs benzyl substituent as the exclusive .... Studies have demonstrated its ability to bind selectively to TRβ-1 with an EC50 of 0.16 μM2015年3月9日—"GC-1dramatically increases the metabolic rate, essentially converting white fat, which stores excess calories and is associated with obesity .... This selective binding is further characterized by high affinity, with GC 1 exhibiting KD values of 67 pM for hTRβ1 and 440 pM for hTRα1. This means GC-1 interacts with the beta receptor significantly more strongly than the alpha receptor, a characteristic that differentiates it from non-selective thyroid hormone mimetics and suggests a more targeted therapeutic approachSelective activation of thyroid hormone signaling pathways ....

The implications of this selective action are far-reaching, particularly in the realm of metabolic health. Research has indicated that GC-1 can significantly influence fat metabolism2024年11月4日—Sobetirome, also known asGC-1, is a selective thyromimetic drug that mimics the action of thyroid hormones. It binds preferentially to the .... For instance, studies in rodents have shown that GC-1 not only prevented fat accumulation (steatosis) but also induced a marked reduction of pre-accumulated fat, notably without significant adverse effects on heart rate.Thyroid Hormone Receptor激动剂、基因 This is a critical finding, as traditional thyroid hormone agonists can often lead to cardiovascular side effects due to their broader impact on the bodySobetirome (GC-1) is a thyroid hormone receptor β (TRβ)-specific agonist which bind selectively to TRβ-1 with an EC50 of 0.16 μM.. The selective signaling of GC-1 appears to mitigate these risks, making it a promising candidate for obesity and metabolic syndrome treatmentThyroid hormone receptor β-specific agonist GC-1 increases ....

Further research highlights the potential of GC-1 to dramatically increase metabolic rate. This is achieved, in part, by converting "bad" white fat, which stores excess calories and is associated with obesity, into "good" brown fat.Nextida GC - Rousselot collagen and gelatin In rat brown adipocytes, GC-1 has been shown to increase Ucp1 mRNA expression and D2 activity stimulated by adrenergic signals. This mechanism of action directly contributes to enhanced energy expenditure and fat loss.Sobetirome - an overview | ScienceDirect Topics Beyond its effects on fat, GC-1 has also demonstrated the ability to lower cholesterol levels. Studies in rats, mice, and monkeys have shown that GC-1 lowers cholesterol with significantly higher potency and efficacy compared to other agents, suggesting its potential in managing dyslipidemia.

The versatility of the GC-1 peptide extends to its potential applications in liver disordersGC 1 (4554) by Tocris, Part of Bio-Techne. Reviewing some of the effects of GC-1 on different liver conditions reveals its possible clinical relevance.Sobetirome | TRβ agonist | Buy from Supplier AdooQ® It has been observed that Sobetirome (GC-1) can impact lipid and bile acid metabolism and induce hepatocyte proliferation downstream of Wnt/β-catenin signaling.

The scientific exploration of GC-1 is supported by ongoing research into its synthesis and characterization. An improved synthesis of this TRβ-selective thyromimetic GC-1 has been described, employing a benzyl substituent as an exclusive component, aiming for greater efficiency.作者：E Rinaldini·2021·被引用次数：2—This study aims to demonstrate TH-selective signaling effects on reproductive and lactational performance in hypothyroid rats. This continuous refinement of synthesis methods is crucial for making the peptide more accessible for further study and potential therapeutic development.

It's important to distinguish GC-1 from other related compounds and concepts. While referred to as a peptide in some contexts, GC-1 is technically a small molecule agonist. The term peptide might arise in discussions of its interaction with receptors or in broader classifications of biomolecules. For instance, a blocking peptide has been developed for Anti-SLC25A22 (GC1) primary antibody, serving as a negative control reagent to confirm antibody specificity, demonstrating another context where "GC1" might appear. However, when discussing the thyromimetic drug itself, Sobetirome or GC-1 are the precise terms.

In summary, the GC-1 peptide (Sobetirome) represents a significant advancement in the development of selective thyroid hormone receptor agonistsActivating thyroid hormone receptor may rev up metabolism. Its ability to mimic thyroid hormone action with enhanced selectivity for TRβ offers a promising therapeutic avenue for conditions such as obesity, metabolic syndrome, and dyslipidemia, while potentially mitigating the side effects associated with less selective agentsThyroid hormone receptor β-specific agonist GC-1 increases .... Continued research into its mechanisms of action, therapeutic benefits, and synthesis will be vital in fully realizing the potential of this remarkable compound作者：GJ Grover·2004·被引用次数：199—For these studies, the TRβ selective agonist,GC-1, was used to assess selectivity for lipid-lowering and metabolic rate changes relative to tachycardia..